Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort. Read more about Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.
Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression. Read more about Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression.
Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group. Read more about Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group.
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Read more about A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future. Read more about RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future.
Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group. Read more about Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group.
The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions. Read more about The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions.
Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs. Read more about Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs.
EXTH-78. CRISPROFF EPIGENOME EDITING AND FUNCTIONAL GENOMICS DEFINE MEDIATORS OF CHEMOTHERAPY RESISTANCE IN GLIOBLASTOMA. Read more about EXTH-78. CRISPROFF EPIGENOME EDITING AND FUNCTIONAL GENOMICS DEFINE MEDIATORS OF CHEMOTHERAPY RESISTANCE IN GLIOBLASTOMA.
EPCO-12. IN VIVO PERTURB-SEQ DEFINES BIOLOGICAL DRIVERS AND THERAPEUTIC VULNERABILITIES UNDERLYING RADIOTHERAPY RESISTANCE IN GLIOBLASTOMA. Read more about EPCO-12. IN VIVO PERTURB-SEQ DEFINES BIOLOGICAL DRIVERS AND THERAPEUTIC VULNERABILITIES UNDERLYING RADIOTHERAPY RESISTANCE IN GLIOBLASTOMA.
